Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Holding HAE?
Track your performance easily
HAE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$69.29 - $97.97
Previous CloseN/A
Volume53.78K
Average Volume (3M)501.97K
Market Cap
$3.69B
Enterprise Value$5.01B
Total Cash (Recent Filing)$139.56M
Total Debt (Recent Filing)$253.63M
Price to Earnings (P/E)30.5
Beta1.06
Next Earnings
Feb 06, 2025EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding50,223,890
10 Day Avg. Volume514,585
30 Day Avg. Volume501,972
Standard Deviation0.12
R-Squared0.03
Alpha-0.00362
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)19.30
P/FCF Ratio23.90
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue3.68
Enterprise Value/Gross Profit7.25
Enterprise Value/Ebitda17.71
Forecast
1Y Price Target
$112.88Price Target Upside53.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Haemonetics News
PremiumCompany Announcements
Haemonetics Announces EVP Josep Llorens’ Retirement
Bulls Say, Bears Say
Bulls Say
Market PositioningManagement's investment in R&D is seen as a step to sustain competitive advantage and differentiate the interventional portfolio, positioning the company as a diversified, high-growth business.
Product InnovationThe redesign and expansion of medical devices like VASCADE XL are seen as key growth drivers for Haemonetics.
Strategic DivestitureThe agreement to sell Whole Blood assets allows Haemonetics to focus more on high-growth and higher-margin segments, such as Hospital and Plasma.
Bears Say
EarningsThe whole blood business divestiture is expected to be modestly EPS dilutive on a net basis, indicating a potential short-term financial impact.
Revenue GuidanceManagement dropped the inorganic revenue contribution by 100 bp in the guide after disappointing on this front in F2Q.
Sales PerformancePlasma sales declined 3% organic in F2Q25 similar to the 3% organic decline in F1Q25 given the CSL transition.
---
Ownership Overview
1.18% Insiders
49.55% Mutual Funds
0.21% Other Institutional Investors
23.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $69.29 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $3.69B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Feb 06, 2025 which is in 19 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Nov 07, 2024. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.073 by $0.047.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.17.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,223,890 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.12 in its last earnings report, beating expectations of $1.073. Following the earnings report the stock price went up 10.709%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
---
Haemonetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$112.88 (53.52% Upside)
$112.88 (53.52% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 7.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.08%
12-Months-Change
Fundamentals
Return on Equity
13.97%
Trailing 12-Months
Asset Growth
25.55%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAE Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented strong performance in the Hospital segment and significant growth in the Vascular Closure business, which were offset by declines in Plasma and Blood Center revenues, and challenges in China. The company maintains a positive outlook with increased guidance for organic revenue growth, reflecting confidence in overcoming current challenges.Read More>---
HAE Stock 12 Month Forecast
Average Price Target
$112.88
▲(53.52% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
28/48 ratings generated profit
1 Year Average Return
+7.80%
reiterated a buy rating last month
Copying Anthony Petrone's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +7.80% per trade.
---